What Do Analysts Say About Immix Biopharma Inc (IMMX)?

Rosalind Gate

Immix Biopharma Inc (IMMX) saw an uptrend of 9.73% in the recent trading with $4.96 being its most recent. The current price level -35.83% lower than the highest price of $7.73 marked by the stock while trading over the past 52-weeks, whereas it is 270.15% higher than the lowest price of $1.34 the company dropped to over past 52-weeks. The latest news story on IMMX appeared in (Benzinga) under the title “Immix Biopharma (IMMX) Shares Slip As Investors Focus On Plans To Offer And Sell $750 Million In Securities”.

Do analysts rate it as a buy, sell or hold?

Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Currently, the stock has been recommended as Strong Buy by 1 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 1.00 for the stock.

Immix Biopharma Inc Earnings – What Happened With IMMX

Coming around sales and income figures on IMMX Stock Income Statement, public trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor.

Immix Biopharma Inc – Insider Activity and Holdings

Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 52.96 million. IMMX does have institutional investors; and they hold 5.46% of the stock.

As on 2024-06-30, AIGH CAPITAL MANAGEMENT LLC was the top most holder in Immix Biopharma Inc (NASDAQ:IMMX) with an ownership of 1.41 million shares of the company or 6.0017 of the stake worth $2.79 million. The filing also reveals BLEICHROEDER LP as the second largest holder in the company with a control over 3.6266 of the outstanding shares. Its stake is worth $1.68 million for having 0.85 million shares in hand.

CABLE CAR CAPITAL LLC also came holding a key position in the company during the recent quarter and it now holds 3.3966 of the outstanding shares. With this there are now 35.0 institutions which have possession in IMMX’s shares.

Key Metrics for IMMX

The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, Immix Biopharma Inc has a debt to equity ratio of 0.13.

Baxter Report
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.